Projects per year
Personal profile
Education
- 2000 Ph.D., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1996 M.S., Graduate Institute of Pharmaceutical Sciences, National Taiwan University
- 1994 B.S., School of Pharmacy, Taipei Medical University
Experience
- 2021- Director, Research Center of Drug Discivery, Taipei Medical University
- 2018- Dean, College of Pharmacy, Taipei Medical University
- 2017- Director, Biomedical Commercialization Center, Taipei Medical University
- 2015-2022 Director, Research Center of Pharmaceutical Sciences and Biotechnology, College of Pharmacy, Taipei Medical University
- 2013-2017 Associate Dean, College of Pharmacy, Taipei Medical University
- 2012-2016 Director, Core Laboratory of Drug Organic Synthesis, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program in Clinical Drug Development of Herbal Medicine, College of Pharmacy, Taipei Medical University
- 2013- Jointly Appointed Professor, Ph.D. Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University
- 2012- Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2008-2012 Associate Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2004-2008 Assistant Professor, School of Pharmacy, College of Pharmacy, Taipei Medical University
- 2000-2004 Postdoctoral Research, Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes
Awards
- 2019 Total Research project Budget Award - Excellence Award, Taipei Medical University
- 2019 Excellent Industry-Academia Collaboration Award, Taipei Medical University
1. EDITORIAL ADVISORY BOARD members, Journal of Medicinal Chemistry (IF = 6.259, CHEMISTRY/MEDICINAL)
2. 2015 Taipei Medical University Teaching Award
3. 2014 Taipei Biotech Awards, Gold “Industry-University Cooperation Award”
4. 2014 TienTe Lee Award, Young Scientist Award
5. 2011 Young scientist award, Ching-Kang Foundation for Pharmacy Promotion
Research Interests
- Discovery and Development of small molecular compounds towards IND
- Structure optimization through rational drug design and intelligent modification
- Medicinal Chemistry
Fingerprint
- 1 Similar Profiles
Network
-
Discovery of Bbb-Crossing Drugs Targeting Neuroinflammation for Glioblastoma( I )
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
Organopalladium Assisted Stitching of Key Antitumor Fragments to Furnish Dual Inhibitory Anticancer Chemical Architectures( II )
8/1/22 → 7/31/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
設計與合成雙效LSD1/HDAC抑制劑作為抗大腸直腸癌之研究
7/1/22 → 2/28/23
Project: A - Government Institution › b - Ministry of Science and Technology
-
合成用於治療腦癌的前列腺素E2抑制劑
1/1/22 → 12/31/22
Project: B - Project of TMU › h - Higher Education Sprout Project
-
代謝質體研究所引發的抗腦癌藥物研發
1/1/22 → 12/31/22
Project: A - Government Institution › f - Other (Funded by Government)
-
Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment
Wu, T. Y., Chen, M., Chen, I. C., Chen, Y. J., Chen, C. Y., Wang, C. H., Cheng, J. J., Nepali, K., Chuang, K. H. & Liou, J. P., Apr 2023, In: Journal of Advanced Research. 46, p. 159-171Research output: Contribution to journal › Article › peer-review
Open Access2 Citations (Scopus) -
Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects
Nepali, K., Wu, A. C., Lo, W. L., Chopra, B., Lai, M. J., Chuang, J. Y. & Liou, J. P., Feb 2023, In: European Journal of Medicinal Chemistry. 248, 115054.Research output: Contribution to journal › Article › peer-review
-
2,6-Difluorobenzamide derivatives as store-operated calcium channel (SOC) inhibitors
Wang, Y. S., Yeh, T. K., Chang, W. C., Liou, J. P., Liu, Y. M. & Huang, W. C., Dec 5 2022, In: European Journal of Medicinal Chemistry. 243, 114773.Research output: Contribution to journal › Article › peer-review
-
Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier
Sharma, R., Chatterjee, E., Mathew, J., Sharma, S., Rao, N. V., Pan, C. H., Lee, S. B., Dhingra, A., Grewal, A. S., Liou, J. P., Guru, S. K. & Nepali, K., Oct 5 2022, In: European Journal of Medicinal Chemistry. 240, 114602.Research output: Contribution to journal › Article › peer-review
2 Citations (Scopus) -
A Potent Histone Deacetylase Inhibitor MPT0E028 Mitigates Emphysema Severity via Components of the Hippo Signaling Pathway in an Emphysematous Mouse Model
Yeh, L-Y., Fang, Y-T., Lee, H-S., Liu, C-H., Chen, Y-Y., Lo, Y-C., Laiman, V., Liou, J-P., Chung, K. F., Chuang, H-C. & Lin, C-H., May 2022, In: Frontiers in Medicine. 9, 794025.Research output: Contribution to journal › Article › peer-review
Open Access
Datasets
-
Additional file 4: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Creator), Liou, J. (Creator), Teng, C. (Contributor) & Pan, S. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202896.v1, https://springernature.figshare.com/articles/Additional_file_4_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202896/1
Dataset
-
Additional file 1: of Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Creator), Liou, J. (Creator), Teng, C. (Contributor) & Pan, S. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.8202881.v1, https://springernature.figshare.com/articles/Additional_file_1_of_Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/8202881/1
Dataset
-
Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma
Tsai, I. (Contributor), Kuo, C. (Contributor), Liou, J. (Creator) & Chang, J. (Contributor), Figshare, 2018
DOI: 10.6084/m9.figshare.c.4052207.v1, https://figshare.com/collections/Novel_microtubule_inhibitor_MPT0B098_inhibits_hypoxia-induced_epithelial-to-mesenchymal_transition_in_head_and_neck_squamous_cell_carcinoma/4052207/1
Dataset
-
Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status
Chao, M. (Contributor), Chang, L. (Contributor), Tu, H. (Contributor), Chang, C. (Contributor), Lai, M. (Contributor), Chen, Y. (Creator), Liou, J. (Creator), Teng, C. (Contributor) & Pan, S. (Contributor), Figshare, 2019
DOI: 10.6084/m9.figshare.c.4522856.v1, https://springernature.figshare.com/collections/Combination_treatment_strategy_for_pancreatic_cancer_involving_the_novel_HDAC_inhibitor_MPT0E028_with_a_MEK_inhibitor_beyond_K-Ras_status/4522856/1
Dataset
-
Suberoylanilide hydroxamic acid represses glioma stem-like cells
Hsu, C. (Contributor), Chang, W. (Creator), Hsu, T. (Contributor), Liu, J. (Contributor), Yeh, S. (Contributor), Wang, J. (Creator), Liou, J. (Creator), Ko, C. (Contributor), Chang, K. (Creator) & Chuang, J. (Creator), Figshare, 2016
DOI: 10.6084/m9.figshare.c.3596465.v1, https://doi.org/10.6084%2Fm9.figshare.c.3596465.v1
Dataset